Kandoset

Amlodipine / Candesartan cilexetil, the active ingredient in Kandoset, is a calcium channel blocker / angiotensin II receptor blocker presented as an oral tablet for oral use. It lowers blood pressure in adults with hypertension.

GNH USA supplies Kandoset as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Kandoset is indicated for conditions affecting the cardiovascular system where blood pressure reduction is required.

- Hypertension: provides additive lowering of systolic and diastolic blood pressure in adults with essential hypertension. - Isolated systolic hypertension: helps control elevated systolic pressure in older patients. - High‑risk cardiovascular patients: contributes to overall risk reduction when combined with lifestyle measures.

Kandoset may cause a range of adverse reactions, which are generally categorized by frequency.

Common Side Effects: - Headache: mild to moderate head pain. - Peripheral edema: swelling of ankles or feet. - Dizziness: sensation of light‑headedness. - Flushing: warmth and redness of the skin. - Fatigue: feeling unusually tired. - Nausea: mild stomach upset.

Serious or Rare Side Effects: - Hypotension: excessively low blood pressure requiring medical attention. - Angio‑edema: swelling of face, lips, tongue or throat. - Elevated liver enzymes: possible indication of liver injury. - Severe allergic reaction: rash, itching, breathing difficulty or anaphylaxis.

Before prescribing Kandoset, clinicians should consider several safety aspects.

- Renal impairment: monitor kidney function and adjust therapy as needed. - Hepatic impairment: use caution in patients with severe liver disease. - Electrolyte imbalance: check potassium levels regularly. - Pregnancy and lactation: safety not established; avoid unless clearly needed. - Concomitant drugs: review for interactions with CYP3A4 inhibitors. - Store at ambient temperature: keep below 25 °C, protect from moisture and light.

Kandoset can interact with other medicines; interactions are grouped by clinical significance.

Major Interactions (Avoid): - Potassium‑sparing diuretics or supplements: risk of hyperkalaemia. - Strong CYP3A4 inhibitors (e.g., itraconazole, clarithromycin): may increase amlodipine exposure. - Aliskiren in diabetic patients: increased risk of renal impairment.

Moderate Interactions (Monitor Closely): - NSAIDs: may attenuate antihypertensive effect. - Lithium: potential increase in lithium concentrations. - Rifampicin: may reduce candesartan plasma levels.